Literature DB >> 17699194

A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance.

Ashita J Tolwani1, Mary B Prendergast, Rajesh R Speer, Brenda S Stofan, Keith M Wille.   

Abstract

Obstacles to the widespread use of continuous renal replacement therapy (CRRT) include the need for anticoagulation, customized solutions, and complex protocols that carry an attendant risk for error, raise cost, and increase pharmacy and nursing workload. However, high solute clearance using CRRT with an effluent rate of 35 ml/kg per h has also recently been associated with improved survival in critically ill patients with acute renal failure. No published CRRT protocols using dilute regional citrate anticoagulation have achieved adequate metabolic control, effective anticoagulation, and high solute clearance in a practical, user-friendly, and economical manner. The safety and the efficacy of continuous venovenous hemodiafiltration at effluent rates of 35 ml/kg per h in critically ill acute renal failure patients were evaluated prospectively using a standardized bicarbonate-based dialysate; a systemic calcium infusion; and two separate trisodium citrate replacement solutions, a 0.67% solution and a 0.5% solution. All patients achieved adequate metabolic control, the desired effluent rate of 35 ml/kg per h, and high solute clearance. Use of the 0.67% citrate replacement solution resulted in mild alkalosis, whereas the 0.5% solution maintained appropriate acid-base balance. There was no difference in dialyzer survival between the 0.67 and 0.5% citrate groups (80 versus 82%; P = 0.60, Kaplan-Meier analysis). Dilute regional citrate as part of a CRRT protocol with a standard 25-mmol/L bicarbonate dialysate provides adequate metabolic control, high diffusive and convective clearance, and excellent dialyzer patency in a practical and cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17699194     DOI: 10.2215/CJN.00040505

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  32 in total

Review 1.  Renal replacement therapy review: past, present and future.

Authors:  Geoffrey M Fleming
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

2.  The Novel PrisMax Continuous Renal Replacement Therapy System in a Multinational, Multicentre Pilot Setting.

Authors:  Marcus Broman; Max Bell; Olivier Joannes-Boyau; Claudio Ronco
Journal:  Blood Purif       Date:  2018-06-19       Impact factor: 2.614

Review 3.  Continuous Renal Replacement Therapy: Who, When, Why, and How.

Authors:  Srijan Tandukar; Paul M Palevsky
Journal:  Chest       Date:  2018-09-25       Impact factor: 9.410

Review 4.  Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: a position statement of the Work Group "Renal Replacement Therapies in Critically Ill Patients" of the Italian Society of Nephrology.

Authors:  Enrico Fiaccadori; Valentina Pistolesi; Filippo Mariano; Elena Mancini; Giorgio Canepari; Paola Inguaggiato; Marco Pozzato; Santo Morabito
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

5.  Recurring extracorporeal circuit clotting during continuous renal replacement therapy resolved after single-session therapeutic plasma exchange.

Authors:  Tibor Fülöp; Adrian Cosmin; Luis A Juncos
Journal:  J Clin Apher       Date:  2011-05-26       Impact factor: 2.821

Review 6.  [Regional citrate anticoagulation in renal replacement therapy in the intensive care station : Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI].

Authors:  M Schmitz; M Joannidis; D Czock; S John; A Jörres; S J Klein; M Oppert; V Schwenger; J Kielstein; A Zarbock; D Kindgen-Milles; C Willam
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-05-08       Impact factor: 0.840

7.  Continuous renal replacement treatment and the 'bleeding patient'.

Authors:  Hugh Davies; Gavin Leslie; David Morgan
Journal:  BMJ Case Rep       Date:  2011-01-11

8.  Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration.

Authors:  Joon-Sung Park; Gheun-Ho Kim; Chong Myung Kang; Chang Hwa Lee
Journal:  Korean J Intern Med       Date:  2011-03-02       Impact factor: 2.884

Review 9.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

10.  Normal citratemia and metabolic tolerance of citrate anticoagulation for hemodiafiltration in severe septic shock burn patients.

Authors:  Filippo Mariano; Luisa Tedeschi; Maurizio Morselli; Maurizio Stella; Giorgio Triolo
Journal:  Intensive Care Med       Date:  2010-05-18       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.